Envista Holdings
NVST
23.04
-0.23
-0.99%
Envista Holdings
US · NVST
#2329 by market cap
Listed 2019
23.04
-0.23
-0.99%
Live - 5344 symbols - heartbeat 275s ago
· 2026-10-08 07:16
Pre-market
23.70
+2.86%
After-hours
23.04
0.00%
- Market cap
- 3.70B
- P/E (TTM)i
- 39.72
- P/Bi
- 1.20
- EPSi
- 0.28
- Div yieldi
- 0.00%
- 52W posi
- 37%
Reader sentiment
Are you bullish or bearish on NVST?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- Total institutional ownership rose 0.5 percentage points.
Institutional ownership
- Held by institutions
- 119.40% +0.48pp
- Institutions
- 451
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund95.52%
Hedge Fund17.11%
Public Company2.28%
Government Pension Fund1.42%
Sovereign Wealth Fund1.37%
Private Company0.93%
Individual/Insider0.39%
Insurance Company0.35%
Family Office/Trust0.34%
Top holders as of 2026-06-30
BlackRock
11.48% · 18.44M sh
Ariel Investments, LLC
6.11% · 9.82M sh
Dimensional Fund Advisors
5.96% · 9.57M sh
Vanguard Capital Management, LLC
5.21% · 8.37M sh
Vanguard Portfolio Management, LLC
4.66% · 7.49M sh
Eaton Vance Management
3.70% · 5.95M sh
Gates Capital Management, Inc.
3.46% · 5.55M sh
State Street Global Advisors
3.32% · 5.33M sh
AllianceBernstein
3.25% · 5.21M sh
Arrowstreet Capital, Limited Partnership
3.02% · 4.85M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Paul Keel | Chief Executive Officer | 0.10% |
| Amir Aghdaei | Chief Executive Officer | 0.08% |
| Barbara Hulit | Independent Director | 0.04% |
| Mark Nance | Senior Vice President | 0.04% |
| Eric Hammes | Chief Financial Officer | 0.03% |
| Stefan Nilsson | President of Nobel Biocare | 0.02% |
| Faez Kaabi | VP, Chief Accounting Officer & Corporate Controller | 0.02% |
| Robert Befidi | President of Diagnostics | 0.02% |
| Mischa Reis | Senior Vice President of Strategy & Corporate Development | 0.02% |
| Veronica Acurio | President of Orthodontics- Ormco | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-24 | Robert Befidi | President of Diagnostics | Sale to Issuer | -5,147 | $27.47 |
| 2026-08-24 | Eric Hammes | Chief Financial Officer | Sale to Issuer | -10,885 | $27.47 |
| 2026-08-24 | Veronica Acurio | President of Orthodontics- Ormco | Sale to Issuer | -7,710 | $27.47 |
| 2026-08-24 | Stefan Nilsson | President of Nobel Biocare | Sale to Issuer | -804 | $27.47 |
| 2026-08-19 | Mischa Reis | Senior Vice President of Strategy & Corporate Development | Automatic Disposition | -8,000 | $27.50 |
| 2026-08-17 | Paul Keel | Chief Executive Officer | Other Acquisition | +179,730 | -- |
| 2026-08-17 | Paul Keel | Chief Executive Officer | Other Derivative Acquisition | +159,900 | -- |
| 2026-08-17 | Eric Hammes | Chief Financial Officer | Other Derivative Acquisition | +47,970 | -- |
| 2026-08-05 | Coree Thomas | Vice President & Global Controller | Initial Statement of Beneficial | 0 | -- |
| 2026-05-24 | Paul Keel | Chief Executive Officer | Sale to Issuer | -12,811 | $23.43 |
| 2026-05-18 | Daniel Raskas | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Christine Tsingos | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Kieran Gallahue | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Richard Huennekens | Independent Chairperson | Other Acquisition | +12,585 | -- |
| 2026-05-18 | Vivek Jain | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | Wendy Carruthers | Independent Director | Other Acquisition | +9,330 | -- |
| 2026-05-18 | J. Pierce | Director | Other Acquisition | +9,330 | -- |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Sale to Issuer | -11,840 | $29.59 |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Other Acquisition | +48,670 | -- |
| 2026-02-24 | Paul Keel | Chief Executive Officer | Other Derivative Acquisition | +115,320 | $29.59 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:16:28 · For reference only, not investment advice and not tailored to your situation.